ArticleLeukemia2021
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.
Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- JAK inhibitors and COVID-19.Journal for immunotherapy of cancer · 2022Pooled it
- Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.Expert review of anti-infective therapy · 2022Pooled it
- Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis.Frontiers in medicine · 2022Pooled it
- Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.Annals of the rheumatic diseases · 2021Pooled it
- Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia.Clinics in chest medicine · 2023Review
- A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia.Inflammation and regeneration · 2023Review
- Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib.Frontiers in medicine · 2023Article
- Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.Frontiers in pharmacology · 2023Review
- Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options.International immunopharmacology · 2022Review
- Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review.World journal of critical care medicine · 2022Article
- New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Therapeutic role of immunomodulators during the COVID-19 pandemic- a narrative review.Postgraduate medicine · 2022Review
- Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection.Physiology (Bethesda, Md.) · 2022Review
- Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling.Drug discovery today · 2022Review
- Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection.Inflammopharmacology · 2022Review
- MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too.Hematology. American Society of Hematology. Education Program · 2021Review
- JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy.Journal of clinical medicine · 2021Article
- COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.Cytokine & growth factor reviews · 2021Review
- Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19.Cell host & microbe · 2021Review
- The Janus Kinase Inhibitor Ruxolitinib Prevents Terminal Shock in a Mouse Model of Arenavirus Hemorrhagic Fever.Microorganisms · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.